CCN2 and neoplasm: A preclinical study demonstrates that the TGF-β receptor inhibitor LY2109761 can downregulate the connective tissue growth factor (CTGF), disrupt tumor-stroma interactions, and significantly inhibit malignant progression, which suggests potential clinical benefits for targeting CTGF (72).